Colorcon acquires Kollicot Coating Systems line from BASF
Company also advances co-operation to offer superior functional coatings for pharmaceutical tablets.
Colorcon and BASF have signed an agreement to further strengthen their co-operation in the area of pharmaceutical film coatings. As part of this agreement, BASF will sell its Kollicoat IR Coating Systems product line to Colorcon; including the current customer business, inventory and relevant know-how. The addition of the Kollicoat IR Coating Systems complements Colorcon’s existing film coating product line and position as a leading innovator of fully formulated film coating systems and provides Kollicoat IR Coating Systems customers with a wide range of film coating options. Final closure of the transaction is subject to review of the Brazilian competition authorities.
By acquiring the Kollicoat IR Coating Systems, Colorcon further strengthens its existing activities with PVA-based pigmented, ready-to-use film coatings, for use on immediate release forms of pharmaceuticals and dietary supplements. Kelly Boyer, General Manager Coatings at Colorcon, explains: “This sale enables both companies to focus on their core competencies, and further strengthens our existing cooperation.” After final closure of the transaction all existing customers of Kollicoat IR Coating Systems will be served by Colorcon from its worldwide production facilities. Both BASF and Colorcon look forward to the opportunity to expand the cooperation between both companies in the film coating area by combining BASF’s polymer expertise and Colorcon’s formulation and application knowledge. Frank Stein, Vice President Global Segment Management Pharma Solutions at BASF, states: “Customers will benefit from both the exceptional functional performance of the products as well as from Colorcon’s worldwide unique, customized services.BASF will focus on developing and promoting innovative film coating polymers including Kollicoat IR. The transfer of Kollicoat IR Coating Systems does not affect BASF’s Kollicoat IR polymer business.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.